Title:
USE OF MULTI-DOMAIN FUSION PROTEIN
Document Type and Number:
WIPO Patent Application WO/2024/041477
Kind Code:
A1
Abstract:
Provided is use of a multi-domain fusion protein in the preparation of a medicament for treating or preventing tumors. The fusion protein comprises an anti-PD-L1 single-domain antibody fragment, a VEGF-antagonizing fragment and a TGF-β binding fragment. The provided multi-domain fusion protein having anti-cancer activity can, in one antibody fusion protein molecule, organically combine the function of an anti-PD-L1 monoclonal antibody in blocking the interaction of PD-L1/PD-1, the function of an anti-VEGF monoclonal antibody in reducing the microvascular growth and inhibiting metastatic diseases, and the function of a TGF-β receptor in relieving the tolerance of cancer cells to TGF-β signals and enhancing the immune response, thus being useful for treating or preventing tumors.
Inventors:
HUANG YANSHAN (CN)
HUANG CAI (CN)
HUANG CAI (CN)
Application Number:
PCT/CN2023/113995
Publication Date:
February 29, 2024
Filing Date:
August 21, 2023
Export Citation:
Assignee:
ZHEJIANG DOER BIOLOGICS CO LTD (CN)
International Classes:
C07K19/00; A61K39/395; A61P35/00; C07K14/495; C07K14/71; C12N15/62; C12N15/63
Domestic Patent References:
| WO2022105832A1 | 2022-05-27 |
Foreign References:
| CN112552412A | 2021-03-26 | |||
| CN112409483A | 2021-02-26 | |||
| CN112638401A | 2021-04-09 | |||
| CN112739717A | 2021-04-30 |
Other References:
LI LINWEI, WEN QINGLIAN, DING RUILIN: "Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials", FRONTIERS IN ONCOLOGY, vol. 12, 26 July 2022 (2022-07-26), XP093008407, DOI: 10.3389/fonc.2022.905520
Download PDF: